The pathway to monitoring quality of care for patients with adenomatous oligopolyposis of unknown etiology

Endoscopy 2022; 54(07): 698-699
DOI: 10.1055/a-1743-2712

Editorial

Referring to Carballal S et al. p. 688–697

Joshua Melson

Department of Digestive Diseases, Rush University Medical Center, Chicago, Illinois, USA

References
1 van Leerdam ME, Roos VH, van Hooft JE. et al. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2019; 51: 877-895
2 Gupta S, Lieberman D, Anderson JC. et al. Recommendations for follow-up after colonoscopy and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastrointest Endosc 2020; 91: 463-485.e5
3 Grover S, Kastrinos F, Steyerberg EW. et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012; 308: 485-492
4 Stanich PP, Pearlman R, Hinton A. et al. Prevalence of germline mutations in polyposis and colorectal cancer–associated genes in patients with multiple colorectal polyps. Clin Gastroenterol Hepatol 2019; 17: 2008-2015.e3
5 Carballal S, Sánchez A, Moreira L. et al. Prevalence of adenomatous polyposis in a fecal immunochemical test-based colorectal cancer screening program and risk of advanced neoplasia during follow-up. Endoscopy 2022; 54: 688-697
6 Alexander JL, Johnston BJ, Smith TJ. et al. Low referral rates for genetic assessment of patients with multiple adenomas in United Kingdom Bowel Cancer Screening Programs. Dis Colon Rectum 2021; 64: 1058-1063
7 Jansen AML, Goel J. Mosaicism in patients with colorectal cancer or polyposis syndromes: a systematic review. Clin Gastroenterol Hepatol 2020; 18: 1949-1960